AU2006202564A1 - Imaging agents for early detection and monitoring of cardiovascular plaque - Google Patents
Imaging agents for early detection and monitoring of cardiovascular plaque Download PDFInfo
- Publication number
- AU2006202564A1 AU2006202564A1 AU2006202564A AU2006202564A AU2006202564A1 AU 2006202564 A1 AU2006202564 A1 AU 2006202564A1 AU 2006202564 A AU2006202564 A AU 2006202564A AU 2006202564 A AU2006202564 A AU 2006202564A AU 2006202564 A1 AU2006202564 A1 AU 2006202564A1
- Authority
- AU
- Australia
- Prior art keywords
- agent
- radionuclide
- cardiovascular
- imaging
- targeting moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012216 imaging agent Substances 0.000 title claims description 63
- 230000002526 effect on cardiovascular system Effects 0.000 title claims description 37
- 238000001514 detection method Methods 0.000 title claims description 9
- 238000012544 monitoring process Methods 0.000 title claims description 9
- 230000008685 targeting Effects 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 27
- 230000007505 plaque formation Effects 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 238000003384 imaging method Methods 0.000 claims description 19
- 210000001519 tissue Anatomy 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- 108010050904 Interferons Proteins 0.000 claims description 12
- 102000014150 Interferons Human genes 0.000 claims description 12
- 229930195725 Mannitol Natural products 0.000 claims description 12
- 230000001413 cellular effect Effects 0.000 claims description 12
- 239000002738 chelating agent Substances 0.000 claims description 12
- 239000000594 mannitol Substances 0.000 claims description 12
- 235000010355 mannitol Nutrition 0.000 claims description 12
- 241000894007 species Species 0.000 claims description 12
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 11
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 11
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 11
- 229940050410 gluconate Drugs 0.000 claims description 11
- 229940095064 tartrate Drugs 0.000 claims description 11
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 10
- 239000003638 chemical reducing agent Substances 0.000 claims description 10
- 239000003102 growth factor Substances 0.000 claims description 10
- 230000003902 lesion Effects 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 9
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 8
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 8
- 238000009825 accumulation Methods 0.000 claims description 8
- 229940047124 interferons Drugs 0.000 claims description 8
- 229940047120 colony stimulating factors Drugs 0.000 claims description 7
- 239000002243 precursor Substances 0.000 claims description 7
- 206010054094 Tumour necrosis Diseases 0.000 claims description 6
- 230000002503 metabolic effect Effects 0.000 claims description 6
- UXWSZFYLVAFLRT-UHFFFAOYSA-N 4-(2-methyl-3h-thiophen-2-yl)pyridine-3-carboxylic acid Chemical group C=1C=NC=C(C(O)=O)C=1C1(C)CC=CS1 UXWSZFYLVAFLRT-UHFFFAOYSA-N 0.000 claims description 5
- 150000007942 carboxylates Chemical group 0.000 claims description 5
- 231100001011 cardiovascular lesion Toxicity 0.000 claims description 5
- 150000002527 isonitriles Chemical class 0.000 claims description 5
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 4
- 230000003143 atherosclerotic effect Effects 0.000 claims description 4
- 210000000748 cardiovascular system Anatomy 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 4
- 210000000497 foam cell Anatomy 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 210000000663 muscle cell Anatomy 0.000 claims 1
- 108020003175 receptors Proteins 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 239000002502 liposome Substances 0.000 description 9
- -1 TGF-P Proteins 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102100031506 Complement C5 Human genes 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002966 stenotic effect Effects 0.000 description 5
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000002872 contrast media Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 230000005298 paramagnetic effect Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- IZCVLYJVVCABBV-UHFFFAOYSA-N 2-hydrazinylpyridine-3-carboxylic acid Chemical compound NNC1=NC=CC=C1C(O)=O IZCVLYJVVCABBV-UHFFFAOYSA-N 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- YXTDAZMTQFUZHK-ZVGUSBNCSA-L (2r,3r)-2,3-dihydroxybutanedioate;tin(2+) Chemical compound [Sn+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O YXTDAZMTQFUZHK-ZVGUSBNCSA-L 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 101710091342 Chemotactic peptide Proteins 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000015689 E-Selectin Human genes 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 101000941598 Homo sapiens Complement C5 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
- KOUZWQLNUJWNIA-UHFFFAOYSA-N 2-hydrazinylpyridine-3-carboxamide Chemical compound NNC1=NC=CC=C1C(N)=O KOUZWQLNUJWNIA-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- OSNZINYBJQTKQS-LAQSRHRBSA-L C([C@H]([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O)O.C([C@H]([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O)O.[Zn+2] Chemical compound C([C@H]([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O)O.C([C@H]([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O)O.[Zn+2] OSNZINYBJQTKQS-LAQSRHRBSA-L 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 101710126321 Pancreatic trypsin inhibitor Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008356 dextrose and sodium chloride injection Substances 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005831 heart abnormality Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Description
110
INO
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Applicant: THE GENERAL HOSPITAL CORPORATION Invention Title: IMAGING AGENTS FOR EARLY DETECTION AND MONITORING OF CARDIOVASCULAR PLAQUE The following statement is a full description of this invention, including the best method of performing it known to me/us: 1A
O
IMAGING AGENTS FOR EARLY DETECTION AND MONITORING OF n 5 CARDIOVASCULAR PLAQUE The present invention is in the field of nuclear medicine. More specifically, the invention relates to imaging of plaque formation in cardiovascular tissue.
N 10 Background of the Invention 0It is estimated that more than 1.5 million myocardial infarctions occur annually in the C"N United States, and at least 500,000 infarctions result in death, usually sudden. (American Heart Association, Heart and Stroke Facts. Dallas, Tex: American Heart Association National Center; 1992). Accordingly, myocardial infarction is the most frequent cause of mortality in the United States; and in most Western countries (Coopers, ES. Prevention: The Key to Progress. Circulation. 1993; 24: 629-632; WHO-MONICA Project. Myocardial Infarction and Coronary Deaths in the World Health Organization Monica Project: Registration Procedures, Event Rates and Care Fatality Rates in 38 Populations From 21 Countries in Four Continents.
Circulation. 1994; 90:583-612). However, even the optimal use of thrombolytic therapy for !0 myocardial infarction, the advance of which the greates attention has been focused, could prevent only 25,000 deaths or 5% of the total, because most deaths occur suddenly, before any type of treatment can be initiated. (Muller, JE, et.al., Acute Risk Factors and Vulnerable Plaques: The Lexicon of a New Frontier. J. Am. Coll. Cardiol. 1994; 23:809-813).
In 1992, Fuster et al., (Fuster V. et al., The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes. N. Engl. J. Med. 1992; 326:242-250.) classified the progression of coronary atherosclerotic disease into five phases. Phase I is represented by a small plaque that is present in most people under the age of 30 years regardless of their country of origin and that usually progresses slowly (types I to III lesions). Phase 2 is represented by a plaque, not necessarily very stenotic, with a high lipid content that is very prone to rupture (types IV and Va lesions). The plaque of phase 23 may rupture with predisposition to change its geometry and to formation of mural thrombus, these processes by definition represent phase 3 (type I lesion), with a subsequent increase in stenosis, possibly resulting in angina, or ischemic sudden death. The mural and occlusive thrombi from plaques of phases 3 and 4, by 2 being organized by connective tissue, may contribute to the progression of the atherosclerotic process represented by severely stenotic or occlusive plaques of phase (types Vb and Vc lesions). The severely stenotic plaques of phase 5, by a phenomenon of stasis and/or deendothelialization, can become complicated by a thrombus and/or rapid myoproliferative response, also leading to.an occlusive plaque of phase 5. Of interest, about two thirds of coronary occlusions are the result of this late stenotic type of plaque and are unrelated to plaque disruption. Unlike the rupture of less-stenotic lipidrich plaques, leading to occlusion and subsequent infarction or other acute coronary syndromes, this process of occlusion from late stenotic plaques tends to be silent because the preceding severe stenosis and ischemia enhance protective collateral circulation. (Fuster, V et al., The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes. N. Engl. J. Med. 1992; 326:242-250; Chesebro, JH et al., Antithrombotic Therapy and Progression of Coronary Artery Disease. Circulation. 1992; 86 (suppl III)).
Sensitive and specific agents are needed to identify the early stages of plaque formation in a subject, the progression of which can then be delayed or reduced by initiation of an appropriate therapeutic regimen or change in lifestyle.
SUMMARY OF THE INVENTION The present invention provides a cardiovascular imaging agent comprising a radionuclide, wherein said imaging agent comprises the product of combining a targeting moiety or precursor thereof with a chelating agent which chelates said radionuclide, wherein said radionuclide is associated with a targeting moiety comprising a component of plaque formation, wherein said radionuclide is associated with said targeting moiety by way of an auxiliary molecule selected from the group H:\suzannet\Keep\Speci\P49147 GENERAL HOSPITAL Div.doc 28/03/03 3 consisting of mannitol, gluconate, glucoheptonate and tartrate, and wherein said targeting moiety is selected from the group consisting of: i) cells, ii) colony stimulating factors, iii) growth factors, iv) cytokines, interferons and tumour necrosis factors, v) cellular sources of energy for metabolic active plaque formation and vi) lipids and lipid receptors.
In general, the invention features imaging agents comprised of a targeting moiety and a label, such as a radionuclide or paramagnetic contrast agent. In preferred embodiments, the labelled imaging agents comprise small molecule that rapidly less than about 24 hours, more preferably less than about 12 hours and most preferably less than about 6 hours) localize, selectively and irreversibly localize at the site of a plaque and rapidly clear from other tissue.
Examples of appropriate radionuclides include: 131, 125, 123 99mTC, 18F, 68Ga, 67Ga, 72As, 89Zr, 64Cu, 62CU, 111In, 203Pb, 198Hg, "Ru, "C and 201 TI. Suitable paramagnetic contrast agents include gadolinium, cobalt, nickel, manganese and iron. Particularly preferred radionuclides or paramagnetic contrast agents have an appropriate halflife and high specific activity.
Particularly preferred targeting moieties comprise components of the processes involved in plaque formation and growth as well as specific bind partners thereto receptors and fragments thereof, receptor ligands, and antibodies and binding fragments thereof).
Particularly preferred targeting moieties are comprised of components of processes involved in plaque formation and growth as well as specific bind partners to such components receptors and fragments thereof, receptor ligands receptor agonists or antagonists), and antibodies and binding fragments thereof). Examples include: cells, including smooth muscle cells, leukocytes, lymphocytes (B-lymphocytes and T-lymphocytes), H:I\e.Zanet\Kee\Speci\P49147 GEN4ERAL H~OSPITAL Div.doc 28/03/03 4 monocytes, macrophages, foam cells, platelets, erythrocytes and polymorphonuclear cells (e.g.
granulocytes and neutrophils) and cellular fragments (e.g.
heme) and analogs thereof porphoryins and phthalocyanines); (ii) colony stimulating factors GM-CSF and CSF-1) and receptors and antibodies thereto; (iii) growth factors transforming growth factors, e.g. TGF-P, endothelial growth factors (e.g.
VEGF) and growth factors that initiate smooth muscle proliferation); (iv) adhesive cell-surface glycoproteins (e.g.
E-selectin, VCAM-1 and VCAM10; and carbohydrates such as 11 C-deoxy-D-glucose and 18F-2-fluorodeoxy-D-glucose); other components of a vascular inflammatory response (for example complement components Cl, Clq, Clr, Cls, C2, C3, C3a, C3b, C4, C4C2, C4C2C3b, C5a, C5b and C5a), immunoglobulins and cytokines e.g. interleukins IL-1, IL-la and IL-13, IL-2; IL-3; IL-6; IL-7; and IL-8) interferons (interferon a, interferon y) and tumor necrosis factors TNF-a)); (vi) cellular sources of energy for metabolically active plaque formation; and (vii) lipids e.g. liposomes, including polyethylene glycol (PEG) coated liposomes, cholesterol and its esters, lipoproteins LDL, HDL, oxidized LDL) and lipid receptors.
In another aspect, the invention relates to methods for making the imaging agents. In a preferred H:\suzannet\Keep\Speci\P49147 GENERAL HOSPITAL Div.doc 28/03/03 4a embodiment, an appropriate label is ionically or covalently associated with the targeting moiety via any of a variety of means. In a preferred embodiment, the association is via incorporation of a chelating structure, such as -N 2
S
2
-NS
3
-N
4 an isonitrile, a hydrazine, a HYNIC (hydrazinonicotinic acid), 2-methylthiolnicotinic acid, phosphorus, or a carboxylate containing group.
The present invention also provides a method of imaging cardiovascular tissue in a mammal, comprising administering to the mammal a cardiovascular imaging agent having a radionuclide, said radionuclide being associated with a targeting moiety comprising a component of plaque formation, wherein said radionuclide is associated with said targeting moiety by way of an auxiliary molecule selected from the group consisting of mannitol, gluconate, glucoheptonate and tartrate, and wherein said targeting moiety is selected from the group consisting of: i) cells, ii) colony stimulating factors, iii) growth factors, iv) cytokines, interferons, and tumour necrosis factors, v) cellular sources of energy for metabolic active plaque formation and vi) lipids and lipid receptors.
The invention features methods for imaging a subject for plaque formation and growth comprising administering to the subject an effective amount of an imaging agent of the invention and detecting the concentration and spatial distribution of the agent using an appropriate detection means, wherein a higher differential accumulation of the agent in a particular location relative to other locations within the cardiovascular tissue of a subject is indicative of plaque formation in the subject and wherein a higher differential accumulation of the agent in a particular location relative to the accumulation detected at the same location in a prior imaging is indicative of plaque growth.
The present invention further provides a kit for cardiovascular imaging, comprising a supply of the imaging H:\suzannet\Keep\Speci\P49147 GENERAL HOSPITAL Div.doc 28/03/03 4b 0 agent or a precursor of the imaging agent having a radionuclide, said radionuclide being associated with a Stargeting moiety comprising a component of plaque formation, wherein said radionuclide is associated with said targeting moiety by way of an auxiliary molecule selected from the group consisting of mannitol, gluconate, glucoheptonate and tartrate, and wherein said targeting moiety is selected from the group consisting of: i) cells, ii) colony stimulating factors, iii) growth factors, ND 10 iv) cytokines, interferons, and tumour necrosis factors, Sv) cellular sources of energy for metabolic active plaque formation and vi) lipids and lipid receptors.
The invention features a kit for imaging which includes, but is not limited to, a supply of the imaging agent or its precursor. The kit may also include at least one chelating structure and a tin containing reducing agent.
The present invention still further provides a cardiovascular imaging agent defined above when used in the detection and monitoring of cardiovascular plaque.
The present invention also provides use of an imaging agent defined above for the manufacture of a medicament for the detection and monitoring of cardiovascular plaque.
Other features or advantages of the present invention will be apparent from the following detailed description and from the claims.
H:\suzannet\Keep\Speci\P49147 GENERAL HOSPITAL Div.doc 28/03/03 Detailed Description of the Preferred Embodiments SFor convenience, the meaning of certain terms and phrases employed in the following Sspecification, examples and appended claims are provided below: An "antibody or fragment thereof' refers to a whole polyclonal or monoclonal antibody ;Z 5 or a binding fragment therof A "chelating structure" refers to any molecule or complex of molecules which bind to both the label and targeting moiety. Examples include: N 2
S
2 structure, an NS 3 structure, an N 4 structure, an isonitrile-containing structure, a hydrazine containing structure, a HYNIC (hydrazinonicotinic acid) group-containing structure, a 2-methylthiolnicotinic acid group- I containing structure, a carboxylate group containing structure, and the like.
N "Cardiovascular disease" or "cardiovascular lesion" refers to any of a variety of disease or lesions to the heart or vasculature of a subject. Examples include atherosclerosis (i.e.
thickening and hardening of arteries due to plaque formation) and related disorders resulting from occluded blood flow angina, cerebral ischemia, renal hypertension, ischemic heart disease, stroke) and thrombus and formation Deep Vein Thrombosis (DVT)).
"Cardiovascular tissue" refers to any and all tissue comprising the cardiovascular system. including: all components of the heart, aortas, arteries coronary and carotid), veins, or components of these tissues and organs.
A "precursor of an imaging agent" refers to any molecule or complexes of molecules which are easily converted to the imaging agent.
A "small molecule" refers to a composition having a molecular weight, which is less than about 5KD, more preferably less than about 4KD, even more preferably less than about 3KD and most preferably less than about 2 KD.
"Subject" refers to an animal, e.g. mammal, particularly a human.
A "targeting moiety or precursor thereof' is any molecule or biological entity that targets cardiovascular tissue or thrombi, or any molecule or biological entity that is easily converted to such a molecule or biological entity.
"thrombus" refers to a clot of blood formed within a blood vessel from a plaque and which remains attached to its place of origin.
"vascular inflammation" refers to vascular tissue damage in a subject, which may result from a number of causes microbial infection, autoimmune processes, any injury or trauma, etc). Regardless of cause, the vascular inflammatory response consists of a complicated set of 6 functional and cellular adjustments involving changes in microcirculation, movement of fluids, proliferation of smooth muscle cells, generation of foam cells and influx and activation of inflammatory cells.
The present invention provides novel imaging agents which are comprised of a targeting moiety and a label. These novel imaging agents specifically accumulate in actively forming or actively growing plaques and therefore are useful for detecting or monitoring plaque formation.
Particularly preferred targeting moieties are comprised of components of processes involved in plaque formation and growth as well as specific bind partners to such components receptors and fragments thereof, receptor ligands receptor agonists or antagonists), and antibodies and binding fragments thereof). Examples include: cells, including smooth muscle cells, leukocytes, lymphocytes (B-lymphocytes and T-lymphocytes), monocytes, macrophages, foam cells, platelets, erythrocytes and polymorphonuclear cells (e.g.
granulocytes and neutrophils) and cellular fragments and analogs thereof porphoryins, such as heme and phthalocyanines); (ii) colony stimulating factors (e.g.
GM-CSF (See U.S. Patent Nos. 5,229,496 and 4,879,227) and CSF-1 (See U.S. Patent Nos. 4,847,201; 4,868,119 and 4,929,700)) and receptors and antibodies thereto; (iii) growth factors transforming growth factors (e.g.
TGF-P), endothelial growth factors VEGF) and growth factors that initiate smooth muscle proliferation), adhesive cell-surface glycoproteins E-selectin, VCAM-1 and VCAM13 (See e.g. U.S. Patent No. 5,272,263) and ICAM-1 (See Rosenfeld, ME et al., Cellularity of Atherosclerotic Lesions Car. Art. Dis. 1994; 5:189-197; Navab, M. et al., Monocyte Adhesion and Transmigration in Atherosclerosis. Cor. Art. Dis. 1994; 5:198-204) and other cell binding molecules (See e.g. Kim, JA et al., Partial Characterization of Leukocyte Binding Molecules on H:\suzannet\Keep\Speci\P49147 GENERAL HOSPITAL Div.doc 28/03/03 7 Endothelial Cells Induced by Minimally Oxidized LDL Arterio. Thromb. 1994; 24:427-433); and carbohydrates such as 11 C-deoxy-D-glucose and 18F-2-fluorodeoxy-D-glucose); (iv) other components of a vascular inflammatory response (for example complement components Cl, Clq, Clr, Cls, C2, C3, C3a, C3b, C4, C34C2, C4C2C3b, C5a, C5b and immunoglobulins and cytokines (e.g interleukins IL-1, IL-la (See U.S. Patent No. 4, 762,914) and IL- (See U.S. Patent No. 4,766,061), IL-2 (See U.S. Patent Nos. 5,037,644; 4,939,903; 4,604,377; and 4,518,584); IL- 3; IL-4 (See U.S. Patent No. 5,017,691); IL-6; IL-7; and IL-8) interferons (interferon a, interferon 7) and tumor necrosis factors TNF-a)); cellular sources of energy for metabolically active plaque formation; and (vi) lipids liposomes, including polyethylene glycol (PEG) coated liposomes, cholesterol and its esters, lipoproteins LDL, HDL, oxidized LDL) and lipid receptors.
In accordance with the invention, the targeting molecule is in association with (spatial proximity to) the label. Spatial proximity between the targeting molecule and the label may be effected in any manner which preserves the specificity of the targeting molecule for its target tissue. For example, spatial proximity between the label and the targeting molecule may be effected by a covalent or non-covalent chemical bond. Such a chemical bond may be effected through a chelating substance and/or an auxiliary molecule such as mannitol, gluconate, glucoheptonate, tartrate and the like. Alternatively, spatial proximity between the label and the targeting molecule may be effected by incorporating the label and the targeting molecule in a micelle or liposome, in such a way that the affinity of the targeting molecule for its target tissue is maintained. Spatial proximity between the label and the targeting molecule may also be effected by attaching the label and the targeting molecule to a matrix such as a microsphere, liposome, or micelle.
H:\suzannet\Keep\Speci\P49147 GENERAL HOSPITAL Div.doc 28/03/03 7a The imaging agents described above may contain any label in accordance with the invention. Highly specific and sensitive labels are provided by radionuclides, which can then be detected, using positron emission tomography (PET) or Single Photon Emission Computed Tomograph (SPECT) imaging. More preferably, the imaging agent of the invention contains a radionuclide selected from the group consisting of 131I, 125I, 123I, 99mTC, 1F, Ga, 6Ga, 72As, 8Zr, Cu, 62Cu, 11In, 203Pb, Hg, C, 9Ru, and 201 TI or a paramagnetic contrast agent, such as gadolinium, cobalt, nickel, manganese and iron. Such labels may be incorporated into the imaging agent by covalent bonding directly to an atom of the targeting molecule, or the label may be non-covalently or covalently associated with the targeting molecule through a chelating structure or through an auxiliary molecule such as mannitol, gluconate, glucoheptonate, tartrate, and the like. When a chelating structure is used to provide spatial proximity between the label and the targeting molecule, the chelating structure may be directly associated with the H:\suzannet\Keep\Speci\P49147 GENERAL HOSPITAL Div.doc 28/03/03 targeting molecule or it may be associated with the targeting molecule through an auxiliary Smolecule such as mannitol, gluconate, glucoheptonate, tartrate, and the like.
Any suitable chelating structure may be used to provide spatial proximity between the radionuclide and the targeting molecule of the agent through covalent or noncovalent association. Many such chelating structures are known in the art. Preferably, the chelating structure is an N 2 S. structure, an NS 3 structure, an N 4 structure, an isonitrile-containing structure, a hydrazine containing structure, a HYNIC (hydrazinonicotinic acid) groupcontaining structure, a 2-methylthiolnicotinic acid group-containing structure, a carboxylate group containing structure, and the like. In some cases, chelation can be achieved without S) including a separate chelating structure, because the radionuclide chelates directly to atom(s) in Sthe targeting moiety, for example to oxygen atoms in various moieties.
The chelating structure, auxiliary molecule, or radionuclide may be placed in spatial proximity to any position of the targeting molecule which does not interfere with the interaction of the targeting molecule with its target site in cardiovascular tissue. Accordingly, the chelating structure, auxiliary molecule, or radionuclide may be covalently or non-covalently associated with any moiety of the targeting molecule except the receptor-binding moiety.
Radionuclides may be placed in spatial proximity to the targeting molecule using known procedures which effect or optimize chelation, association, or attachment of the specific radionuclide to ligands. For example, when '2I is the radionuclide, the imaging agent may be labeled in accordance with the known radioiodination procedures such as direct radioiodination with chloramine T, radioiodination exchange for a halogen or an organometallic group, and the like. When the radionuclide is 9 Tc, the imaging agent may be labeled using any method suitable for attaching ""Tc to a ligand molecule. Preferably, when the radionuclide is 9 mTc, an auxiliary molecule such as mannitol, gluconate, glucoheptonate, or tartrate is included in the labeling reaction mixture, with or without a chelating structure. More preferably, 9"'Tc is placed in spatial proximity to the targeting molecule by reducing 99 mTcO, with tin in the presence of mannitol and the targeting molecule. Other reducing agents, including tin tartrate or non-tin reductants such as sodium dithionite, may also be used to make the cardiovascular imaging agent of the invention.
In general, labeling methodologies vary with the choice of radionuclide, the moiety to be labeled and the clinical condition under investigation. Labeling methods using and '"In are described for example in Peters, A.M. et al., Lancet 2: 946-949 (1986); Srivastava, S.C. et al., Semin. Nucl. Med. 14(2):68-82 (1984); Sinn, H. et al., Nucl. Mea. ('.tuttgart) 13:180, 1984); McAfee, J.G. et al., J. Nucl. Med. 17:480-487, 1976; McAfee, J.G. et al., J.
Nucl. Med. 17:480-487, 1976; Welch, M.J. et al., J. Nucl. Med. 18:558-562, 1977; McAfee,.
et al., Semin. Nucl. Med. 14(2):83, 1984; Thakur, et al., Semin. Nucl. Med.
14(2):107, 1984; Danpure, H.J. et al., Br. J. Radiol., 54:597-601, 1981; Danpure, H.J. et al., Br. J. Radiol. 55:247-249, 1982; Peters, A.M. et al., J. Nucl. Med. 24:39-44, 1982; Gunter, K.P. et al., Radiology 149:563-566, 1983; and Thakur, M.L. et al., J. Nucl. Med. 26:518-523, 1985.
After the labeling reaction is complete, the reaction mixture may optionally be purified 3 using one or more chromatography steps such as Sep Pack or high performance liquid IND chromatography (HPLC). Any suitable HPLC system may be used if a purification step is performed, and the yield of cardiovascular imaging agent obtained from the HPLC step may be optimized by varying the parameters of the HPLC system, as is known in the art. Any HPLC parameter may be varied to optimize the yield of the cardiovascular imaging agent of the invention. For example, the Ph may be varied, raised to decrease the elution time of the peak corresponding to the cardiovascular imaging agent of the invention.
The invention as embodied in a kit for imaging comprises one or more of the imaging agents described above, in combination with a pharmaceutically acceptable carrier such as human serum albumin. Human serum albumin for use in the kit of the invention may be made in any way, for example, through purification of the protein from human serum or though recombinant expression of a vector containing a gene encoding human serum albumin. Other substances may also be used as carriers in accordance with this embodiment of the invention, for example, detergents, dilute alcohols, carbohydrates, auxiliary molecules, and the like. The kit of the invention may of course also contain such other items as may facilitate its use, such as syringes, instructions, reaction vials, and the like.
In one embodiment, a kit according to the invention contains from about I to about mCi of the radionuclide-labeled cardiovascular imaging agent described above, in combination with a pharmaceutically acceptable carrier. The cardiovascular imaging agent and carrier may be provided in solution or in lyophilized form. When the cardiovascular imaging agent and carrier of the kit are in lyophilized form, the kit may optionally contain a sterile and physiologically acceptable reconstitution medium such as water, saline, buffered saline, and the like.
In another embodiment, the kit of the invention may contain the uniaDetea targeting molecule which has been covalently or non-covalently combined with a chelating agent; an auxiliary molecule such as mannitol, gluconate, glucoheptonate, tartrate, and the like; and a reducing agent such as SnCI 2 or tin tartrate. The unlabeled targeting molecule/chelating agent and the auxiliary molecule may be present as separate components of the kit or they may be combined into one kit component. The unlabeled targeting molecule/chelating agent, the auxiliary molecule, and the reducing agent may be provided in solution or in lyophilized form, and these components of the kit of the invention may optionally contain stabilizers such as NaCI, silicate, phosphate buffers, ascorbic acid, gentisic acid, and the like. Additional 0 stabilization of kit components may be provided in this embodiment, for example, by providing the reducing agent in an oxidation-resistant form.
Determination and optimization of such stabilizers and stabilization methods are well within the level of skill in the art. When the unlabeled targeting molecule/chelating agent of this embodiment are in lyophilized form, the kit may optionally contain a sterile and physiologically acceptable reconstitution medium such as water, saline, buffered saline, and the like. The amounts of unlabeled targeting molecule/chelating agent, auxiliary molecule, and reducing agent in this embodiment can be optimized in accordance with the methods for making the cardiovascular imaging agent set forth above. Radionuclides, including, but not limited to, e.g. obtained from a commercially available "Mo/" 9 'Tc generator or 0 commercially available 1 2 l, may be combined with the unlabeled targeting molecule/chelating agent and the reducing agent for a sufficient period of time and at a temperature sufficient to chelate the radionuclide to the targeting molecule/chelating agent, and the imaging agent thus formed is injected into the patient.
The cardiovascular imaging agents of the invention may be used in accordance with the methods of the invention by those of skill in the art, by specialists in nuclear medicine, to image plaque in the cardiovascular system of a subject. Images are generated by virtue of differences in the spatial distribution of the imaging agents which accumulate in the various tissues and organs of the subject. The spatial distribution of the imaging agent accumulated may be measured using any suitable means, for example, a gamma camera, a PET apparatus, a SPECT apparatus, and the like. Some cardiovascular lesions may be evident when a less intense spot appears within the image, indicating the presence of tissue in which a lower concentration of imaging agent accumulates relative to the concentration of imaging agent which accumulates in surrounding cardiovascular tissue. Alternatively, a caratovascuiar tesion S might be detectable as a more intense spot within the image, indicating a region of enhanced concentration of the imaging agent at the site of the lesion relative to the concentration of agent which accumulates in surrounding cardiovascular tissue. Thrombi and embolisms are S examples of cardiovascular lesions which accumulate enhanced concentrations of the imaging S agents of the invention. Accumulation of lower or higher amounts of the imaging at the site of a lesion may readily be detected visually, by inspection of the image of the cardiovascular S tissue. Alternatively, the extent of accumulation of the imaging agent may be quantified using
C
tt) known methods for quantifying radioactive emissions. A particularly useful imaging approach employs more than one imaging agent to perform simultaneous studies. For example, C simultaneous studies of perfusion and metabolic function would allow study of coupling and uncoupling of flow of metabolism, thus facilitating determinations of tissue viability after a cardiac injury. Such determinations are useful in diagnosis of cardiac ischemia, cardiomyopathy, tissue viability, hibernating heart, and other heart abnormalities.
An effective amount of an imaging agent comprising at least one targeting molecule and a label from about I to about 50 mCi of a radionuclide) may be combined with a pharmaceutically acceptable carrier for use in imaging studies. In accordance with the invention, "an effective amount" of the imaging agent of the invention is defined as an amount sufficient to yield an acceptable image using equipment which is available for clinical use. An effective amount of the imaging agent of the invention may be administered in more than one injection. Effective amounts of the imaging agent of the invention will vary according to factors such as the degree of susceptibility of the individual, the age, sex, and weight of the individual, idiosyncratic responses of the individual, the dosimetry. Effective amounts of the imaging agent of the invention will also vary according to instrument and film-related factors.
Optimization of such factors is well within the level of skill in the art. In general, the effective amount will be in the range of from about 0.1 to about 10 mg by injection or from about 5 to about 100mg. orally for use with MRI.
As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, absorption delaying agents, and the like. The formulation used in the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art. The use of such media and agents for pharmaceutically active substances is well known in the art. Supplementary active compounds can also be incorporated into the imaging agent or the invention. The imaging agent of the invention may further be administered to an individual Sin an appropriate diluent or adjuvant, co-administered with enzyme inhibitors or in an appropriate carrier such as human serum albumin or liposomes. Pharmaceutically acceptable Sdiluents include sterile saline and other aqueous buffer solutions. Adjuvants contemplated herein include resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and nhexadecyl polyethylene ether. Enzyme inhibitors include pancreatic trypsin inhibitor, 1" diethylpyrocarbonate, and trasylol. Liposomes inhibitors include water-in-oil-in-water CGF 0 n emulsions as well as conventional liposomes (Strejan et al., J Neuroimmunol 7:27 [1984]).
SThe subject imaging agents can be administered to a subject in accordance with any means that facilitates accumulation of the agent in a subject's cardiovascular system.
D Preferably, the imaging agent of the invention is administered by arterial or venous injection, and has been formulated as a sterile, pyrogen-free, parenterally acceptable aqueous solution.
The preparation of such parenterally acceptable solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred formulation for intravenous injection should contain, in addition to the cardiovascular imaging agent, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art.
The amount of imaging agent used for diagnostic purposes and the duration of the imaging study will depend upon the nature and severity of the condition being treated, on the nature of therapeutic treatments which the patient has undergone, and on the idiosyncratic responses of the patient. Ultimately, the attending physician will decide the amount of imaging agent to administer to each individual patient and the duration of the imaging study.
The present invention is further illustrated by the following examples, which should not be construed as limiting in any way. The contents of all cited references (including literature references, issued patents, published patent applications) as cited throughout this application are hereby expressly incorporated by reference.
Example: Preparation of Radiolabeled Chemotactic Peptide For-MLF For-MLF is a bacterial product that initiates leukocyte chemotaxis by binding to high affinity receptors on white blood cell membranes (Showell et al., J Exp Med 143:1154-1169 [1976], Schiffmann et al., Proc Natl Acad Sci USA 72:1059-1062 [1975], Williams et al., Proc Nati Acad Sci 74:1204-1208 [1977]). These receptors are present on both polymorpnonuclear ^0 leukocytes and mononuclear phagocytes. Due to the very small size of For-MLF (MW 437), Sits molecular structure can be readily manipulated to design an optimal imaging agent.
The labelled chemotactic peptide can be synthesized and purified by the techniques 5 described in Babich et al., J Nucl Med 34:1964-1974 (1993).
Dimethylformamide (DMF) (2 ml) and 60 pl of diisopropylethylamine is added to 186 mg of N-For-Met-Leu-Phe-diaminohexyl amide followed by 154 mg succinimidyl-6-t-BOChydrazinopyridine-3-carboxylic acid in 1 ml DMIF. The mixture becomes yellow and the peptide dissolves within a short time. After 2 hours, ether is added to the reaction mixture and the upper layer is discarded. Water is added to the oily residue causing a solid to form. The solid is washed with 5% sodium bicarbonate, water and ethyl acetate, and the yield is determined. The t-BOC protecting group is removed by stirring the crude product with 5 ml of trifluoroacetic acid (TFA) containing 0.1 ml of p-cresol for 15 min. at 200C. Prolonged treatment with TFA results in increased levels of a side product. The TFA is removed by rotary evaporation, and ether is added to the residue to precipitate the deprotected peptide.
The product is purified by reverse phase HPLC on a 2.5 x 50 cm Whatman ODS-3 column is eluted with a gradient ofacetonitrile in 0.1% TFA. Fractions containing the major component is combined and the solvent is removed to yield the desired product.
Technetium-99m-pertechnetate ("Mo/ 9 "'Tc generator) and stannous glucoheptonate (Glucoscan) are obtained from New England Nuclear (Boston, MA). Technetium-99mglucoheptonate is used to provide the necessary Tc(V) oxo species for radiolabeling the hydrazinonicotinamide conjugated peptides. Approximately 2.S ml of"'Tc-pertechnetate in 0.9% ofNaCI is added to the freeze-dried kit. The final radioactive concentration is 5-10 mCi/ml and radiochemical purity of the product is determined by instant thin-layer silica gel chromatography (ITLC-sg) using both acetone and 0.9% NaCI as mobile phase solvents.
Approximately 0.2 mg of peptide is dissolved in 50 pl dimethylsulfoxide and the solution is diluted to a final concentration of 0.1 mg/ml with 0. I1 M acetate buffer pH 5.2.
Peptide solution (0.5 ml) is placed in a clean glass vial and 0.5ml of 9 'Tc-glucoheptonate is added. The mixture is vortexed briefly and is allowed to stand at room temperature for 1 hour.
Radiochemical purity is determined by ITLC-sg in three solvent systems: acetone, 0.9% NaCI, and acetone and water Equivalents 14 Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
For the purposes of this specification it will be clearly understood that the word "comprising" means "including but not limited to", and that the word "comprises" has a corresponding meaning.
H:\suznnet\Keep\Seci\P49147 GENERAL HOSPITAL Div.doc 28/03/03
Claims (19)
1. A cardiovascular imaging agent comprising a radionuclide, wherein said imaging "agent comprises the product of combining a targeting moiety or precursor thereof with a chelating agent which chelates said radionuclide, wherein said radionuclide is associated with a targeting moiety comprising a component of plaque formation, wherein said radionuclide is associated with said targeting moiety by way of an auxiliary molecule selected from the group consisting of mannitol, gluconate, glucoheptonate and tartrate, and wherein said targeting moiety is selected from the group consisting of: i) cells, ii) colony stimulating factors, iii) growth factors, iv) cytokines, interferons and tumour necrosis factors, v) cellular sources of energy for metabolic active plaque formation and vi) lipids and lipid receptors.
2. The agent of claim 1, wherein said cells are muscle cells, macrophages, foam cells, monocytes, polymorphonuclear cells, cellular fragments or analogs thereof.
3. The agent of claim 1 or claim 2, wherein said colony stimulating factor is a platelet of factor 4.
4. The agent of any one of claims 1 to 3, wherein said radionuclide is selected from the group consisting of 123I, 99mTc, 18, 6Ga, "Cu, and "'In.
The agent of any one of claims 1 to 4, wherein said radionuclide is 99 mTc.
6. The agent of any one of claims 1 to 5, wherein said plaque is an atherosclerotic plaque. H:\suzannet\Keep\Speci\P49147 GENERAL HOSPITAL Div.doc 28/03/03 16
7. The agent of any one of claims 1 to 6, wherein said chelating agent is selected from the group consisting of: an N 2 S 2 structure, and NS 3 structure, and N 4 structure, an isonitrile, a hydrazine, a HYNIC structure, a 2- methylthiolnicotinic acid structure and a carboxylate structure.
8. A method of imaging cardiovascular tissue in a mammal, comprising administering to the mammal a cardiovascular imaging agent having a radionuclide, said radionuclide being associated with a targeting moiety comprising a component of plaque formation, wherein said radionuclide is associated with said targeting moiety by way of an auxiliary molecule selected from the group consisting of mannitol, gluconate, glucoheptonate and tartrate, and wherein said targeting moiety is selected from the group consisting of: i) cells, ii) colony stimulating factors, iii) growth factors, iv) cytokines, interferons, and tumour necrosis factors, v) cellular sources of energy for metabolic active plaque formation and vi) lipids and lipid receptors.
9. The method of claim 8, wherein the method detects a cardiovascular lesion in a mammal, said method comprising the steps of administering to the mammal said imaging agent, detecting the spatial distribution of said agent accumulated in the mammal's cardiovascular system, wherein a detected accumulation of said agent in a region which is different from the detected accumulation of said agent in other regions is indicative of a lesion.
The method of claim 9, wherein said cardiovascular lesion is an atherosclerotic lesion.
11. A kit for cardiovascular imaging, comprising a supply of the imaging agent or a precursor of the imaging agent having a radionuclide, said radionuclide being H:\suzannet\Keep\Speci\P49147 GENERAL HOSPITAL Div.doc 28/03/03 17 associated with a targeting moiety comprising a component of plaque formation, wherein said radionuclide is associated with said targeting moiety by way of an auxiliary molecule selected from the group consisting of mannitol, gluconate, glucoheptonate and tartrate, and wherein said targeting moiety is selected from the group consisting of: i) cells, ii) colony stimulating factors, iii) growth factors, iv) cytokines, interferons, and tumour necrosis factors, v) cellular sources of energy for metabolic active plaque formation and vi) lipids and lipid receptors.
12. The kit of claim 11, further comprising at least one chelating agent and a reducing agent.
13. The kit of claim 12, wherein said reducing agent contains tin.
14. The kit of any one of claims 11 to 13, wherein the radionuclide of said imaging agent is selected from the group consisting of 123, 99mTc, 6Ga, 62Cu, and 111 in" i In.
The kit of any one of claims 11 to 14, wherein the radionuclide is 99 mTc.
16. The kit of claim 12, wherein said chelating agent is selected from the group consisting of: an N 2 S 2 structure, and NS 3 structure, and N 4 structure, an isonitrile, a hydrazine, a HYNIC structure, a 2- methylthiolnicotinic acid structure and a carboxylate structure.
17. A cardiovascular imaging agent according to any one of claims 1 to 7 when used in the detection and monitoring of cardiovascular plaque. H:\suzannet\Keep\Speci\P49147 GENERAL HOSPITAL Div.doc 28/03/03 18
18. Use of an imaging agent according to any of claims 1 to 7 for the manufacture of a medicament for the detection and monitoring of cardiovascular plaque.
19. Cardiovascular imaging agents, methods of imaging involving them, kits containing them or uses of detection and monitoring of cardiovascular plaque involving them, substantially as hereinbefore described with reference to the example. H:\su~armet\Keep\S~,eci\P4914'7 GENERAL HOSPITAL Oiv.doc 28/03103
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08925213 | 1997-09-08 | ||
AU2003203449A AU2003203449A1 (en) | 1997-09-08 | 2003-03-28 | Imaging agents for early detection and monitoring of cardiovascular plaque |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003203449A Division AU2003203449A1 (en) | 1997-09-08 | 2003-03-28 | Imaging agents for early detection and monitoring of cardiovascular plaque |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2006202564A1 true AU2006202564A1 (en) | 2006-07-06 |
AU2006202564B2 AU2006202564B2 (en) | 2008-11-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2823357B2 (en) | Cardiovascular disease detection | |
Stratton et al. | Selective uptake of radiolabeled annexin V on acute porcine left atrial thrombi | |
Goodwin et al. | Indium-111-labeled autologous platelets for location of vascular thrombi in humans | |
Lu et al. | Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue | |
US5886142A (en) | Radiolabeled thrombus imaging agents | |
US5380646A (en) | Thrombus detection using radiolabelled disintegrins | |
US7438891B2 (en) | Imaging agents for early detection and monitoring of cardiovascular plaque | |
Bleeker-Rovers et al. | Radiolabeled compounds in diagnosis of infectious and inflammatory disease | |
Palabrica et al. | Thrombus imaging in a primate model with antibodies specific for an external membrane protein of activated platelets. | |
JPH10504534A (en) | Radiolabeled annexin-galactose conjugate | |
van der Laken et al. | Radiolabeled interleukin-8: specific scintigraphic detection of infection within a few hours | |
JP2002534447A (en) | Compounds for targeting and imaging infection and inflammation | |
US7060251B1 (en) | Imaging agents for early detection and monitoring of cardiovascular plaque | |
Corstens et al. | Chemotactic peptides: new locomotion for imaging of infection? | |
JPH03505094A (en) | Synthetic peptides for arterial imaging | |
Nishigori et al. | Radioiodinated peptide probe for selective detection of oxidized low density lipoprotein in atherosclerotic plaques | |
Pallela et al. | Imaging Thromboembolism with Tc-99m–Labeled Thrombospondin Receptor Analogs TP-1201 and TP-1300 | |
Knight et al. | Comparison of iodine-123-disintegrins for imaging thrombi and emboli in a canine model | |
Fang et al. | SPECT imaging of myocardial infarction using 99mTc-labeled C2A domain of synaptotagmin I in a porcine ischemia–reperfusion model | |
AU2006202564A1 (en) | Imaging agents for early detection and monitoring of cardiovascular plaque | |
AU2003203449A8 (en) | Imaging agents for early detection and monitoring of cardiovascular plaque | |
US20090117032A1 (en) | Imaging Agents for Early Detection and Monitoring of Cardiovascular Plaque | |
JP2000507233A (en) | New ternary complex radiopharmaceuticals | |
Klem et al. | Detection of deep venous thrombosis by DMP 444, a platelet IIb/IIIa antagonist: a preliminary report | |
MXPA00002376A (en) | Imaging agents for early detection and monitoring of cardiovascular plaque |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |